143691-37-6

Basic information

• Product Name: 1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone
• CAS NO: 143691-37-6
• Molecular Formula: C₁₉H₁₉N₃O₃
• Molecular Weight: 337.3725
• Mol File: 143691-37-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 528.9°C at 760 mmHg
• Flash Point: 273.7°C
• Density: 1.37g/cm³
• Vapor Pressure: 2.84E-11mmHg at 25°C
• Refractive Index: 1.674
• CAS DataBase Reference: 1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone(143691-37-6)
• EPA Substance Registry System: 1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone(143691-37-6)

Safety Data

• Hazardous Substances Data: 143691-37-6(Hazardous Substances Data)

Usage

General Description

1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone is a chemical compound with a complex molecular structure. It is a benzodiazepine derivative, which is a class of psychoactive drugs known for their sedative and anxiety-reducing effects. The compound contains a dioxolo ring, a phenyl group, and an ethanone moiety, all of which contribute to its pharmacological activity. This chemical exhibits central nervous system depressant effects and is commonly used as an anxiolytic, hypnotic, sedative, and muscle relaxant. Additionally, it may also have anticonvulsant and amnestic properties. The precise mechanism of action of 1-[5-(4-aminophenyl)-8-methyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone is not fully understood, but it is thought to enhance the effects of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, leading to its therapeutic effects.

Upstream product

• 114460-08-1 GYKI 52895 

Downstream Products

• 143692-53-9 GYKI-53391 

Relevant articles and documents

N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1 means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2 means a C1-3 alkyl group; or R1 and R2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3 means hydrogen or a C1-4 alkanoyl group; R4 represents hydrogen; a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1 means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2 means a C1-3 alkyl group; or R1 and R2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3 means hydrogen or a C1-4 alkanoyl group; R4 represents hydrogen; a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropane-carbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-Acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) Rstands for a C1 6 aliphatic acyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1 4 alkylamino, di(C1 4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1 5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2means a C1 3 alkyl group; or R1 and R2together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3means hydrogen or a C1 4 aliphatic acyl group; R4represents hydrogen; a C1 6 aliphatic acyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1 4 alkylamino, di(C1 4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C1 5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.